There are no data regarding overdosage of chikungunya virus vaccine.
Chikungunya virus (CHIKV) is a member of the Alphavirus genus that was first identified in Tanzania in 1952.A262051 It is spread primarily by the bite of infected mosquitos of the Aedes genus. Infection with CHIKV causes chikungunya fever, an illness characterized by acute fever and severe, persistent arthralgia.A262051 Prior to 2013, chikungunya virus cases and outbreaks had been identified in countries in Africa, Asia, Europe, and the Indian and Pacific Oceans. In late 2013, the first cases were identified in the Caribbean, and it has since spread to most of the Americas.L48786 There are no approved treatments for active chikungunya virus infection.L48731
Chikungunya vaccine (live, attenuated) - marketed under the name Ixchiq - was approved by the FDA in November 2023, becoming the first and only vaccine indicated for the prevention of disease caused by chikungunya virus.L48726 It is approved for use in patients 18 years of age and older who are at high-risk of exposure to chikungunya virus.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Etanercept | The risk or severity of infection can be increased when Chikungunya vaccine (live, attenuated) is combined with Etanercept. |
| Peginterferon alfa-2a | The risk or severity of infection can be increased when Chikungunya vaccine (live, attenuated) is combined with Peginterferon alfa-2a. |
| Interferon alfa-n1 | The risk or severity of infection can be increased when Chikungunya vaccine (live, attenuated) is combined with Interferon alfa-n1. |
| Interferon alfa-n3 | The risk or severity of infection can be increased when Chikungunya vaccine (live, attenuated) is combined with Interferon alfa-n3. |
| Peginterferon alfa-2b | The risk or severity of infection can be increased when Chikungunya vaccine (live, attenuated) is combined with Peginterferon alfa-2b. |
| Anakinra | The risk or severity of infection can be increased when Chikungunya vaccine (live, attenuated) is combined with Anakinra. |
| Interferon gamma-1b | The risk or severity of infection can be increased when Chikungunya vaccine (live, attenuated) is combined with Interferon gamma-1b. |
| Interferon alfa-2a | The risk or severity of infection can be increased when Chikungunya vaccine (live, attenuated) is combined with Interferon alfa-2a. |
| Aldesleukin | The risk or severity of infection can be increased when Chikungunya vaccine (live, attenuated) is combined with Aldesleukin. |
| Adalimumab | The risk or severity of adverse effects can be increased when Adalimumab is combined with Chikungunya vaccine (live, attenuated). |
| Gemtuzumab ozogamicin | The risk or severity of infection can be increased when Chikungunya vaccine (live, attenuated) is combined with Gemtuzumab ozogamicin. |
| Pegaspargase | The risk or severity of infection can be increased when Chikungunya vaccine (live, attenuated) is combined with Pegaspargase. |
| Infliximab | The risk or severity of infection can be increased when Chikungunya vaccine (live, attenuated) is combined with Infliximab. |
| Interferon beta-1b | The risk or severity of infection can be increased when Chikungunya vaccine (live, attenuated) is combined with Interferon beta-1b. |
| Interferon alfacon-1 | The risk or severity of infection can be increased when Chikungunya vaccine (live, attenuated) is combined with Interferon alfacon-1. |
| Trastuzumab | The risk or severity of infection can be increased when Chikungunya vaccine (live, attenuated) is combined with Trastuzumab. |
| Rituximab | The risk or severity of infection can be increased when Chikungunya vaccine (live, attenuated) is combined with Rituximab. |
| Basiliximab | The risk or severity of infection can be increased when Chikungunya vaccine (live, attenuated) is combined with Basiliximab. |
| Muromonab | The risk or severity of infection can be increased when Chikungunya vaccine (live, attenuated) is combined with Muromonab. |
| Ibritumomab tiuxetan | The risk or severity of infection can be increased when Chikungunya vaccine (live, attenuated) is combined with Ibritumomab tiuxetan. |
| Tositumomab | The risk or severity of infection can be increased when Chikungunya vaccine (live, attenuated) is combined with Tositumomab. |
| Alemtuzumab | The risk or severity of infection can be increased when Chikungunya vaccine (live, attenuated) is combined with Alemtuzumab. |
| Cyclosporine | The risk or severity of infection can be increased when Chikungunya vaccine (live, attenuated) is combined with Cyclosporine. |
| Alefacept | The risk or severity of infection can be increased when Chikungunya vaccine (live, attenuated) is combined with Alefacept. |
| Efalizumab | The risk or severity of infection can be increased when Chikungunya vaccine (live, attenuated) is combined with Efalizumab. |
| Antithymocyte immunoglobulin (rabbit) | The risk or severity of infection can be increased when Chikungunya vaccine (live, attenuated) is combined with Antithymocyte immunoglobulin (rabbit). |
| Interferon alfa-2b | The risk or severity of infection can be increased when Chikungunya vaccine (live, attenuated) is combined with Interferon alfa-2b. |
| Natalizumab | The risk or severity of infection can be increased when Chikungunya vaccine (live, attenuated) is combined with Natalizumab. |
| Daclizumab | The risk or severity of infection can be increased when Chikungunya vaccine (live, attenuated) is combined with Daclizumab. |
| Phenylalanine | The risk or severity of infection can be increased when Chikungunya vaccine (live, attenuated) is combined with Phenylalanine. |
| Flunisolide | The risk or severity of infection can be increased when Chikungunya vaccine (live, attenuated) is combined with Flunisolide. |
| Bortezomib | The risk or severity of infection can be increased when Chikungunya vaccine (live, attenuated) is combined with Bortezomib. |
| Cladribine | The risk or severity of infection can be increased when Chikungunya vaccine (live, attenuated) is combined with Cladribine. |
| Carmustine | The risk or severity of infection can be increased when Chikungunya vaccine (live, attenuated) is combined with Carmustine. |
| Amsacrine | The risk or severity of infection can be increased when Chikungunya vaccine (live, attenuated) is combined with Amsacrine. |
| Bleomycin | The risk or severity of infection can be increased when Chikungunya vaccine (live, attenuated) is combined with Bleomycin. |
| Chlorambucil | The risk or severity of infection can be increased when Chikungunya vaccine (live, attenuated) is combined with Chlorambucil. |
| Raltitrexed | The risk or severity of infection can be increased when Chikungunya vaccine (live, attenuated) is combined with Raltitrexed. |
| Mitomycin | The risk or severity of infection can be increased when Chikungunya vaccine (live, attenuated) is combined with Mitomycin. |
| Bexarotene | The risk or severity of infection can be increased when Chikungunya vaccine (live, attenuated) is combined with Bexarotene. |
| Vindesine | The risk or severity of infection can be increased when Chikungunya vaccine (live, attenuated) is combined with Vindesine. |
| Floxuridine | The risk or severity of infection can be increased when Chikungunya vaccine (live, attenuated) is combined with Floxuridine. |
| Fluorometholone | The risk or severity of infection can be increased when Chikungunya vaccine (live, attenuated) is combined with Fluorometholone. |
| Indomethacin | The risk or severity of infection can be increased when Chikungunya vaccine (live, attenuated) is combined with Indomethacin. |
| Tioguanine | The risk or severity of infection can be increased when Chikungunya vaccine (live, attenuated) is combined with Tioguanine. |
| Vinorelbine | The risk or severity of infection can be increased when Chikungunya vaccine (live, attenuated) is combined with Vinorelbine. |
| Dexrazoxane | The risk or severity of infection can be increased when Chikungunya vaccine (live, attenuated) is combined with Dexrazoxane. |
| Beclomethasone dipropionate | The risk or severity of infection can be increased when Chikungunya vaccine (live, attenuated) is combined with Beclomethasone dipropionate. |
| Sorafenib | The risk or severity of infection can be increased when Chikungunya vaccine (live, attenuated) is combined with Sorafenib. |
| Streptozocin | The risk or severity of infection can be increased when Chikungunya vaccine (live, attenuated) is combined with Streptozocin. |
| Trifluridine | The risk or severity of infection can be increased when Chikungunya vaccine (live, attenuated) is combined with Trifluridine. |
| Gemcitabine | The risk or severity of infection can be increased when Chikungunya vaccine (live, attenuated) is combined with Gemcitabine. |
| Betamethasone | The risk or severity of infection can be increased when Chikungunya vaccine (live, attenuated) is combined with Betamethasone. |
| Teniposide | The risk or severity of infection can be increased when Chikungunya vaccine (live, attenuated) is combined with Teniposide. |
| Epirubicin | The risk or severity of infection can be increased when Chikungunya vaccine (live, attenuated) is combined with Epirubicin. |
| Chloramphenicol | The risk or severity of infection can be increased when Chikungunya vaccine (live, attenuated) is combined with Chloramphenicol. |
| Lenalidomide | The risk or severity of infection can be increased when Chikungunya vaccine (live, attenuated) is combined with Lenalidomide. |
| Altretamine | The risk or severity of infection can be increased when Chikungunya vaccine (live, attenuated) is combined with Altretamine. |
| Zidovudine | The risk or severity of infection can be increased when Chikungunya vaccine (live, attenuated) is combined with Zidovudine. |
| Cisplatin | The risk or severity of infection can be increased when Chikungunya vaccine (live, attenuated) is combined with Cisplatin. |
| Oxaliplatin | The risk or severity of infection can be increased when Chikungunya vaccine (live, attenuated) is combined with Oxaliplatin. |
| Cyclophosphamide | The risk or severity of infection can be increased when Chikungunya vaccine (live, attenuated) is combined with Cyclophosphamide. |
| Vincristine | The risk or severity of infection can be increased when Chikungunya vaccine (live, attenuated) is combined with Vincristine. |
| Fluorouracil | The risk or severity of infection can be increased when Chikungunya vaccine (live, attenuated) is combined with Fluorouracil. |
| Desoximetasone | The risk or severity of infection can be increased when Chikungunya vaccine (live, attenuated) is combined with Desoximetasone. |
| Propylthiouracil | The risk or severity of infection can be increased when Chikungunya vaccine (live, attenuated) is combined with Propylthiouracil. |
| Pentostatin | The risk or severity of infection can be increased when Chikungunya vaccine (live, attenuated) is combined with Pentostatin. |
| Methotrexate | The risk or severity of infection can be increased when Chikungunya vaccine (live, attenuated) is combined with Methotrexate. |
| Carbamazepine | The risk or severity of infection can be increased when Chikungunya vaccine (live, attenuated) is combined with Carbamazepine. |
| Vinblastine | The risk or severity of infection can be increased when Chikungunya vaccine (live, attenuated) is combined with Vinblastine. |
| Fluticasone propionate | The risk or severity of infection can be increased when Chikungunya vaccine (live, attenuated) is combined with Fluticasone propionate. |
| Fluocinolone acetonide | The risk or severity of infection can be increased when Chikungunya vaccine (live, attenuated) is combined with Fluocinolone acetonide. |
| Linezolid | The risk or severity of infection can be increased when Chikungunya vaccine (live, attenuated) is combined with Linezolid. |
| Imatinib | The risk or severity of infection can be increased when Chikungunya vaccine (live, attenuated) is combined with Imatinib. |
| Triamcinolone | The risk or severity of infection can be increased when Chikungunya vaccine (live, attenuated) is combined with Triamcinolone. |
| Clofarabine | The risk or severity of infection can be increased when Chikungunya vaccine (live, attenuated) is combined with Clofarabine. |
| Prednisone | The risk or severity of infection can be increased when Chikungunya vaccine (live, attenuated) is combined with Prednisone. |
| Pemetrexed | The risk or severity of infection can be increased when Chikungunya vaccine (live, attenuated) is combined with Pemetrexed. |
| Flumethasone | The risk or severity of infection can be increased when Chikungunya vaccine (live, attenuated) is combined with Flumethasone. |
| Fludrocortisone | The risk or severity of infection can be increased when Chikungunya vaccine (live, attenuated) is combined with Fludrocortisone. |
| Mycophenolate mofetil | The risk or severity of infection can be increased when Chikungunya vaccine (live, attenuated) is combined with Mycophenolate mofetil. |
| Daunorubicin | The risk or severity of infection can be increased when Chikungunya vaccine (live, attenuated) is combined with Daunorubicin. |
| Hydrocortisone | The risk or severity of infection can be increased when Chikungunya vaccine (live, attenuated) is combined with Hydrocortisone. |
| Irinotecan | The risk or severity of infection can be increased when Chikungunya vaccine (live, attenuated) is combined with Irinotecan. |
| Methimazole | The risk or severity of infection can be increased when Chikungunya vaccine (live, attenuated) is combined with Methimazole. |
| Mometasone | The risk or severity of infection can be increased when Chikungunya vaccine (live, attenuated) is combined with Mometasone. |
| Etoposide | The risk or severity of infection can be increased when Chikungunya vaccine (live, attenuated) is combined with Etoposide. |
| Sulfasalazine | The risk or severity of infection can be increased when Chikungunya vaccine (live, attenuated) is combined with Sulfasalazine. |
| Dacarbazine | The risk or severity of infection can be increased when Chikungunya vaccine (live, attenuated) is combined with Dacarbazine. |
| Temozolomide | The risk or severity of infection can be increased when Chikungunya vaccine (live, attenuated) is combined with Temozolomide. |
| Penicillamine | The risk or severity of infection can be increased when Chikungunya vaccine (live, attenuated) is combined with Penicillamine. |
| Prednisolone | The risk or severity of infection can be increased when Chikungunya vaccine (live, attenuated) is combined with Prednisolone. |
| Tacrolimus | The risk or severity of infection can be increased when Chikungunya vaccine (live, attenuated) is combined with Tacrolimus. |
| Sirolimus | The risk or severity of infection can be increased when Chikungunya vaccine (live, attenuated) is combined with Sirolimus. |
| Mechlorethamine | The risk or severity of infection can be increased when Chikungunya vaccine (live, attenuated) is combined with Mechlorethamine. |
| Azacitidine | The risk or severity of infection can be increased when Chikungunya vaccine (live, attenuated) is combined with Azacitidine. |
| Carboplatin | The risk or severity of infection can be increased when Chikungunya vaccine (live, attenuated) is combined with Carboplatin. |
| Methylprednisolone | The risk or severity of infection can be increased when Chikungunya vaccine (live, attenuated) is combined with Methylprednisolone. |
| Dactinomycin | The risk or severity of infection can be increased when Chikungunya vaccine (live, attenuated) is combined with Dactinomycin. |
| Cytarabine | The risk or severity of infection can be increased when Chikungunya vaccine (live, attenuated) is combined with Cytarabine. |